

Stago Webinar



RECORDED WEBINAR

SAVE THE DATE

Tuesday October 5, 2021, 2 p.m. CEST

Vaccine-induced thrombotic thrombocytopenia (VITT):
Pathophysiology, diagnosis and management of a rare COVID-19
vaccination complication

Professor Yves Gruel

Service d'Hématologie-Hémostase
Centre Régional de Traitement de l'Hémophilie
Hôpital Trousseau, CHRU de Tours (France)



Vaccine-induced thrombotic thrombocytopenia (VITT):

Pathophysiology, diagnosis and management of a rare COVID-19 vaccination complication

Since the Coronavirus disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), more than 200 million cases of infection have been reported worldwide, with a fatality rate of around 2%. Fundamental to the response was the development of vaccines capable of thwarting COVID-19 disease, hospitalizations, and associated deaths.

Vaccination is critical to effectively contain the pandemic. Building on already existing knowledge, COVID-19 vaccines development have accelerated at an unimaginable speed,

allowing more than 2.5 billion individuals to be vaccinated. None or only benign side-effects are observed in the vast majority of vaccinees. However, in some extremely rare cases, a few vaccinees may experience a life threatening adverse event, the vaccine-induced thrombotic thrombocytopenia (VITT). In this webinar, attendees will learn on the definition and pathophysiological mechanisms involved in this critical manifestation, as well as on its clinical and laboratory diagnosis and management.



© Professeur Yves Gruel

Professor Yves Gruel,

Yves Gruel was born in 1955, is a physician, a hospital practitioner in hematology and since 1993, a University Professor at the François Rabelais University of Tours. He was trained in Tours, but also in Paris (1984-85) at the Inserm U150 unit and in the United States at the Blood Center Research Institute in Milwaukee (1991-92).

Head of the Hematology-Hemostasis Department at the Trousseau Hospital in Tours between 1993 and 2018, he practiced a biological and clinical activity focused on congenital or acquired disorders of hemostasis.

He coordinates the Competence Center on Hemophilia and Hemorrhagic Diseases of the Centre Region in Tours.

Yves Gruel was also between 2013 and 2019 President of the French Study Group on Hemostasis and Thrombosis, or GFHT. He has an international expertise in platelet immunology, particularly on heparin-induced thrombocytopenia. He was also chairman of the Platelet Immunology subcommittee of the International Society of Hemostasis and Thrombosis (ISTH).

He has co-authored more than 200 scientific or medical articles published in international journals such as Blood, Circulation, Journal of Thrombosis and Haemostasis or Thrombosis and Haemostasis. He is currently the editor-in-chief of the Revue francophone d'Hémostase et Thrombose.